Fecal hemoglobin concentration as a measure of risk to tailor colorectal cancer screening: Are we there yet?

European Journal of Cancer Prevention

Volumn 24, Issue 4, 2015, Pages 321-327

  Garcia, Montse ^a   Milà, Núria ^a   Binefa, Gemma ^a   Benito, Llúcia ^a,b   Gonzalo, Núria ^a   Moreno, Víctor ^a,c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b Departments of C Fundamental Care Medical Surgical Nursing   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Colorectal cancer; Fecal hemoglobin; Organized screening; Risk stratification

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COLON POLYP; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; DEMOGRAPHY; FECES ANALYSIS; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; ADENOMA; CARCINOMA; CHEMISTRY; COHORT ANALYSIS; COLON; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; FECES; IMMUNOCHEMISTRY; MIDDLE AGED; OCCULT BLOOD; PATHOLOGY; PROCEDURES; RECTUM;

ADENOMA; AGED; CARCINOMA; COHORT STUDIES; COLON; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OCCULT BLOOD; RECTUM;

EID: 84930752880     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000090     Document Type: Article

References (37)

1. Allison JE, Fraser CG, Halloran SP, Young GP (2012). Comparing fecal immu-nochemical tests: improved standardization is needed. Gastroenterology 142:422-424.
2. Australian Government Department of Health and Ageing (2005). The Australian Bowel Cancer Screening Pilot Program and beyond: final evaluation report. Screening monograph no. 6/2005. Canberra: Commonwealth of Australia.
3. Borràs JM, Colomer C, Soria P, López R (2010). Priorities for cancer control in Spain. Ann Oncol 21 (Suppl 3):iii111-iii114.
4. Bulliard JL, Garcia M, Blom J, Senore C, Mai V, Klabunde C (2014). Sorting out measures and definitions of screening participation to improve comparability: the example of colorectal cancer. Eur J Cancer 50:434-446.
5. Cancer Strategy of the Spanish National Health System (2009). Update approved by the National Health System Interterritorial Council on October 22, 2009. Madrid: Ed Centro de Publicaciones. Ministerio de Sanidad, Servicios Sociales e Igualdad; 2013. Avaliable at: http://www.msssi.gob.es/organiza cion/sns/planCalidadSNS/pdf/Cancer-Strategy-of-the-Spanish-2009.pdf.
6. Chen LS, Yen AM, Chiu SY, Liao CS, Chen HH (2011). Baseline fecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 12:551-558.
7. Chen LS, Yen AM, Fraser CG, Chiu SY, Fann JC, Wang PE, et al. (2013). Impact of faecal haemoglobin concentration on colorectal cancer mortality and all-cause death. BMJ Open 3:e003740.
8. Ciatto S, Martinelli F, Castiglione G, Mantellini P, Rubeca T, Grazzini G, et al. (2007). Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 96:218-221.
9. Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C (2012). High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10:633-638.
10. Digby J, Fraser CG, Carey FA, McDonald PJ, Strachan JA, Diament RH, et al. (2013). Faecal haemoglobin concentration is related to severity of colorectal neoplasia. J Clin Pathol 66:415-419.
11. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK (2012). Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 9:e1001352.
12. Fraser CG (2012). A future for faecal haemoglobin measurements in the medical laboratory. Ann Clin Biochem 49:518-526.
13. Fraser CG, Mathew CM, McKay K, Carey FA, Steele RJ (2008). Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut 57:1256-1260.
14. Fraser CG, Allison JE, Halloran SP, Young GP. Expert Working Group on Fecal Immunochemical Tests for Hemoglobin, Colorectal Cancer Screening Committee, World Endoscopy Organization (2012). A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 104:810-814.
15. Fraser CG, Halloran SP, Allison JE, Young GP (2013). Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Clin Chem Lab Med 51:2065-2067.
16. García Martínez M, Binefa Rodríguez G, Milà Díaz N, Rodríguez Moranta F, Gonzalo Diego N, Muñoz Sánchez C, et al. (2011). Evaluating colorectal cancer screening strategies (immunological test vs biochemical test) in Catalonia, Spain 2008-2010. Rev Esp Salud Publica 85:593-602.
17. Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S, et al. (2004). Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev 13:19-26.
18. Grazzini G, Ventura L, Zappa M, Ciatto S, Confortini M, Rapi S, et al. (2010). Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 59:1511-1515.
19. Halloran SP, Launoy G, Zappa M. International Agency for Research on Cancer (2012). European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition-faecal occult blood testing. Endoscopy 44 (Suppl 3):SE65-SE87.
20. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008). Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol 103:1541-1549.
21. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al. (2010). Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59:62-68.
22. Legido-Quigley H, Urdaneta E, Gonzalez A, La Parra D, Muntaner C, Alvarez-Dardet C, et al. (2013). Erosion of universal health coverage in Spain. Lancet 382:1977.
23. Leuraud K, Jezewski-Serra D, Viguier J, Salines E (2013). Colorectal cancer screening by guaiac faecal occult blood test in France: evaluation of the programme two years after launching. Cancer Epidemiol 37:959-967.
24. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. (2007). A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 146:244-255.
25. Liao CS, Lin YM, Chang HC, Chen YH, Chong LW, Chen CH, et al. (2013). Application of quantitative estimates of fecal hemoglobin concentration for risk prediction of colorectal neoplasia. World J Gastroenterol 19:8366-8372.
26. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. United States Multi-Society Task Force on Colorectal Cancer (2012). Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143:844-857.
27. Malila N, Palva T, Malminiemi O, Paimela H, Anttila A, Hakulinen T, et al. (2011). Coverage and performance of colorectal cancer screening with the faecal occult blood test in Finland. J Med Screen 18:18-23.
28. Martin-Moreno JM, Anttila A, von Karsa L, Alfonso-Sanchez JL, Gorgojo L (2012). Cancer screening and health system resilience: keys to protecting and bolstering preventive services during a financial crisis. Eur J Cancer 48:2212-2218.
29. McDonald PJ, Strachan JA, Digby J, Steele RJ, Fraser CG (2011). Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer. Clin Chem Lab Med 50:935-940.
30. Omata F, Shintani A, Isozaki M, Masuda K, Fujita Y, Fukui T (2011). Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals. Eur J Gastroenterol Hepatol 23:1036-1041.
31. Peris M, Espinàs JA, Muñoz L, Navarro M, Binefa G, Borràs JM. Catalan Colorectal Cancer Screening Pilot Programme Group (2007). Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen 14:81-86.
32. Spanish Screening Programs Network (2014). Available at: http://www.cribado cancer.org/. [Accessed 26 January 2014].
33. Sweetser S, Smyrk TC, Sinicrope FA (2013). Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol 11:760-767, quiz e54-e55.
34. Thomson S, Jowett M, Evetovits T, Jakab M, McKee M, Figueras J (2013). Summary: health, health systems and economic crisis in Europe. Impact and policy implications. WHO Europe: European Observatory on Health systems and Policies.
35. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. (2008). Random comparison of guaiac and immuno-chemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135:82-90.
36. von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, et al. (2011). Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol 40:712-718.
37. Yen AM, Chen SL, Chiu SY, Fann JC, Wang PE, Lin SC, et al. (2014). A new insight into fecal hemoglobin concentration-dependent predictor for color-ectal neoplasia. Int J Cancer 135:1203-1212.